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Objectives: To compare the analgesic profile of remifentanil patient-controlled analgesia 
(RPCA) and combined spinal-epidural analgesia technique (CSEA) in multiparous women 
during the entire labour. We hypothesized that CSEA would provide a better and more 
sustained pain reduction than RPCA.  
Material and methods: A prospective observational trial under ID NCT02963337 at a 
university hospital in Slovenia 2017–2018. Analgesic efficacy, satisfaction with pain-relief, 
adverse effects, labour progress, and outcomes between RPCA (80) and CSEA (81) were 
compared.  
Results: CSEA provided significantly lower pain scores during the entire labour. Compared 
to baseline, significant pain reduction was recorded in both groups after 15 min. No difference 
was recorded compared to baseline with RPCA and CSEA after 45 and 90 mins, respectively. 
CSEA provided higher satisfaction than RPCA (5 [5–5] vs 5 [4–5], p < 0.0001). More patients 
with CSEA opted for the same technique for the next labour [CSEA; 77 (95%) vs RPCA; 65 
(81%), p = 0.003]. No crossovers were observed. RPCA was associated with desaturation 
(34%), bradypnea (21%) and apnoea (25%), which were transitional and easily managed. 
None had severe sedation. No differences were recorded in labour progress and outcomes. 
Apgar scores were reassuring in all neonates (> 8). None had umbilical artery pH < 7.0.  
Conclusions: In multiparas, CSEA provided superior analgesia and satisfaction than RPCA. 
Nevertheless, RPCA provided a satisfactory experience, suggesting it could be used when 
neuraxial analgesia is not available, preferred, or contraindicated. In that case, constant 
presence of midwife is mandatory for management of clinically significant hypoventilation. 
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In multiparous women, many clinicians choose the combined spinal-epidural analgesia 
technique (CSEA) for labour analgesia due to its fast onset and a higher pain intensity 
reduction in the first 30 minutes compared to epidural analgesia [1]. When not immediately 
available, contraindicated or not preferred by the women or obstetricians, alternatives are 
required. 
Remifentanil patient-controlled analgesia (RPCA) has a suitable profile for labour analgesia. 
Fast set-up, onset and a short duration of action make it particularly attractive for women with 
a faster labour progression [2]. A previous trial observed a higher satisfaction rate with pain 
relief in the RPCA subgroup of multiparous women compared with the epidural group [3]. 
Since the pain intensity was assessed as a secondary outcome and the CSEA technique proved 
advantageous compared to epidural analgesia, further studies comparing CSEA and RPCA are 
needed to allow multiparous women to make informed choices concerning pain-relieving 
potencies of available analgesic techniques.  
Objectives 
To our knowledge, the strategies of RPCA and CSEA have never been directly compared in a 
group of multiparous women. Thus, the primary aim of our study was to compare the pain 
intensity profiles of CSEA and RPCA during the whole labour using an 11-point numerical 
rating scale. The secondary outcomes were overall satisfaction with pain-relief, the incidence 




MATERIAL AND METHODS 
This prospective observational study was approved by the Republic of Slovenia National 
Medical Ethics Committee (Permit No. 91/04/16) and registered at the central database of 
ClinicalTrials.gov under the trial ID NCT02963337, 
(https://clinicaltrials.gov/ct2/show/NCT02963337?term=02963337&rank=1) on November 
15, 2016. The study was conducted from January 2017 to September 2018 in the labour and 
delivery unit of the Perinatology Department, Division of Obstetrics and Gynaecology, 
University Medical Centre Ljubljana, with 6000 deliveries per year, neuraxial and 
remifentanil analgesia rate of 60% (ratio 1:1) and caesarean section rate of 21%.  
Consecutively admitted at the labour and delivery suit, multiparous women with singleton 
pregnancies in their active phase of first stage labour requesting pain relief were asked to 
participate in the study. They were informed about the two different analgesic options being 
studied, i.e., RPCA and CSEA, their advantages and disadvantages. After signing an informed 
consent form, they were allocated either to a RPCA or CSEA group based on their informed 
choices of labour analgesia. The inclusion criteria were age 18 to 55, American Society of 
Anaesthesiologists (ASA) physical status 2 or 3, uncomplicated pregnancy at 37 0/7–40 6/7 
weeks of gestation, absence of known foetal congenital abnormalities, vertex presentation, 
ongoing uterine contraction, cervical dilation 3 to 6 cm and normal cardiotocography (CTG). 
Exclusion criteria were preeclampsia, contraindications to CSEA (coagulation and 
neurological abnormalities, infection/fever) and remifentanil (opioid drug abuse, pethidine 
given within the two previous hours, known allergic reaction to remifentanil, morbid obesity 
with body mass index (BMI) > 40 and obstructive sleep apnoea).  
In the RPCA group, the women were introduced to the PCA pump (Rythmic™ Evolution, 
Micrel Medical Devices, Athens, Greece) and told to use PCA at the start of each uterine 
contraction [4]. Remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) was 
diluted in saline to a concentration of 40 µg mL-1 and administered stepwise from 20 to a 
maximum of 40 µg with a bolus duration of 20 seconds and 2 minutes lockout interval with 
no background infusion. Dose adjustment was performed by the anaesthesiology staff at 
patient’s request. The bolus dose was increased if pain intensity as assessed by an 11-point 
numerical rating scale (NRS; 0 is no pain and 10 the worst imaginable pain) increased and a 
patient’s respiratory rate was > 9 breaths min-1, oxygen saturation (SpO2) ≥ 94%, heart rate > 
50 min-1 and sedation score ≤ 2 on a five-point categorical scale (scale 1–5: 1 = alert, 2 = 
slightly drowsy, 3 = drowsy, 4 = very drowsy, 5 = unarousable) [5–7]. The use of PCA was 
 
 
allowed until 5–10 minutes prior to cord clamping. Women in the RPCA group had 
one-to-one midwifery care. In accordance with the institutional standard operating protocol, 
women were continuously monitored with Capnostream® capnograph (Oridion®, Jeruzalem, 
Israel) with an oral-nasal cannula, sampling from both the nose and mouth (Oridion®). 
Supplemental oxygen (2 l min-1) was given to all patients via a nasal catheter. The respiratory 
monitor recorded continuous waveform of end tidal CO2, respiratory rate, SpO2 and heart rate 
with the alarms being activated by oxygen desaturation (SpO2 < 94 %), bradypnea 
(respiratory rate < 8 min-1) and apnoea longer than 20 seconds, triggering staged interventions 
started with a verbal command to take a deep breath or a light tap in case of no response [8]. 
The anaesthesia provider recorded the triggered alarms from the monitor hourly. Foetal heart 
rate was continuously monitored with CTG (Hewlett Packard Viridia Series 50IP®, Hewlett 
Packard, Palo Alto, CA, USA or Philips 50XM®, Amsterdam, Netherlands). Remifentanil was 
stopped if pathological CTG changes occurred including decreased variability, bradycardia, 
tachycardia, or late decelerations.  
In the CSEA group, all blocks were performed in the sitting position. The epidural space was 
located with an 18-gauge Tuohy needle (PORTEX® CSE cure® Combined Spinal Epidural 
System, Smiths Medical, Minnesota, USA) inserted in the midline using loss of resistance to 
air or saline at the L3-L4 or L4-L5 interspace, followed by needle-through-needle insertion of 
27-gauge spinal needle. After obtaining a cerebrospinal fluid, 2.5 mg bupivacaine 
hydrochloride with 25 µg of fentanyl (total volume of 1 mL) was injected, followed by a 
20-gauge multi-hole catheter insertion into the epidural space [1]. Epidural anaesthesia was 
managed using patient-controlled boluses of 6 mL of 0.1 % bupivacaine with 2 µg mL-1 
fentanyl every 15 minutes with no background infusion via the PCA pump (Rhythmic™ 
Evolution, Micrel Medical Devices, Athens, Greece). In accordance with local protocol, 5 mg 
of ephedrine was injected intravenously into all women immediately after the intrathecal 
analgesic injection to prevent hypotension. 
Demographic and medical data were obtained by means of personal interviews before 
initiation of analgesia and during the labour. Pain intensity was assessed using an 11-point 
NRS, where 0 is no pain and 10 the worst imaginable pain. NRS scores, sedation level, 
automatic readings of non-invasive systolic and diastolic blood pressure, heart rate and SpO2 
were recorded immediately before starting the PCA (baseline), every 15 minutes during the 
first hour and every 30 minutes thereafter. Immediately after delivery, satisfaction with pain 
relief was evaluated using a five-point categorical scale (5 = very good, 4 = good, 3 = 
 
 
moderate, 2 = poor, 1 = very poor). At the same time, each parturient was also asked if she 
would choose the same analgesic technique for her next delivery or recommend it to others.  
Data on labour progress (first and second stage labour duration, mean cervical dilation rate) 
and labour outcome were recorded for each patient, including the use of oxytocin, cumulative 
dose of oxytocin administered, and mode of delivery (spontaneous vaginal, instrumental 
vaginal, caesarean section). Cervical dilation was assessed by the midwife, and all changes 
were recorded until the delivery was completed. The mean cervical dilation rate was defined 
as 10 minus the cervical dilatation observed at the last examination before the start of 
analgesia divided by the duration of labour [9].  
The total dose of remifentanil was registered automatically in the PCA pump and recorded for 
each patient. Data concerning nausea, vomiting and itching were also collected. Oral 
temperature was measured both at the onset of analgesia and within 1 hour of delivery. After 
delivery, Apgar scores at 1 and 5 minutes were recorded, and umbilical blood gas analysis 
performed according to the standard procedures. Neonatal need for naloxone and resuscitation 
were also noted. 
Statistical analysis 
The sample size was calculated based on the primary outcome of pain relief during CSEA in 
multiparous women measured on an 11-point scale ranging from 0 to 10. If the true difference 
between the two studied groups is 1 (on 11-point scale with estimated standard deviation of 
2.2), we needed to study 77 subjects in each group to be able to reject the null hypothesis that 
the population means of the two groups are not equal with probability (power) of 0.8. The 
Type I error probability associated with the test of this null hypothesis is 0.05 [10]. The 
Shapiro-Wilk test was used to evaluate the data for normality. If the normality and equal 
variance assumptions were met, it was followed by Student’s t test; otherwise, the Mann 
Whitney U test was used. Proportions were compared using Fisher’s exact test. NRS scores at 
different time points during labour were compared using mixed-effect analysis followed by 
Sidak post-hoc tests that corrected the p values for the subgroup analyses and Friedman test. 
Statistical analysis was performed with the GraphPad Prism 8 (GraphPad Software, San 
Diego CA, USA). The difference was considered statistically significant at p < 0.05. The data 
are presented as frequency (proportion %), mean ± standard deviation (SD) and median [inter-





One hundred and sixty-two multiparous women were enrolled in the study. One hundred and 
sixty-one delivered vaginally. Caesarean section was performed on one parturient due to 
dystocia (Fig. 1). Demographic data and obstetric end points are presented in Table 1. No 
differences were recorded between the groups except for one cumulative dose of oxytocin 
which was higher in the CSEA group.  
CSEA provided significantly lower pain scores compared to RPCA up to 150 min of labour 
duration (Tab. 2). After 15 min, a significant pain reduction was recorded in both groups. 
After 45 min, the pain reduction was no longer statistically significant from the baseline in the 
RPCA group. In the CSEA group, by contrast, the pain reduction remained statistically 
significant from the baseline up to 90 min (Fig. 2).  
CSEA provided higher satisfaction rate with labour analgesia compared to RPCA (5 [5–5] vs 
5 [4–5], p < 0.0001). More patients from the CSEA group opted for the same technique for 
their next labour [CSEA; 77 (95%) vs RPCA; 65 (81%), p = 0.003]. No difference between 
techniques was recorded in recommending the respective technique to others [CSEA; 77 
(95%) vs RPCA; 72 (90%), p = 0.12]. No crossovers were observed. 
Drug consumption and side effects are presented in Table 3. No differences were observed in 
the incidence of nausea and vomiting, or body temperature between the groups. Pruritus was 
more frequent with CSEA. Maternal hypotension and bradycardia were rare with no 
differences recorded between the groups. Two women with RPCA were drowsy, the rest were 
either alert or slightly drowsy. In the CSEA group, by contrast, all women except one were 
alert. RPCA was associated with periods of desaturation, bradypnea and apnoea which were 
transitional and easily managed. No serious respiratory depression or other serious 
complication occurred. Apgar scores were reassuring in all neonates (> 8), both at 1 and 5 




This study has shown a superiority of CSEA over RPCA for labour analgesia in multiparous 
women. Our results reaffirm that no policy of opioid analgesia during labour is as effective as 
epidural pain relief [11]. Nevertheless, both CSEA and RPCA provided fast onset of analgesia 
with the efficacy ratio of 100% versus 25% in favour of CSEA which lasted up to 30 min. 
Thereafter, CSEA provided consistent pain reduction, whereas with RPCA the pain scores 
increased reaching the pre-treatment level within an hour. This, however, does not imply a 
lack of remifentanil analgesic efficacy as pain scores are known to increase during labour 
[12]. This is particularly true for multiparas where a dramatic increase in pain intensity is 
observed at the end of first-stage labour and during the second-stage due to rapid and abrupt 
foetal descent [13]. To improve the pain management in this group of women, RPCA should 
be initiated later in the first-stage labour with a faster dose increase over time [12, 14]. Similar 
analgesic efficacy of remifentanil has been reported by others using dose range like ours [2, 4, 
15]. When higher bolus doses were used much lower pain scores were achieved on the 
account of severe sedation and desaturation which points to a narrow analgesic window of 
remifentanil [6].  
We observed a higher satisfaction rate with CSEA than RPCA which could be attributed to 
complete pain relief followed by more efficacious labour analgesia. Nevertheless, RPCA still 
provided a satisfactory experience, as demonstrated by the majority (83%) of women grading 
their satisfaction with pain relief as good or very good, and the absence of crossovers 
indicating that other favourable factors were considered more important than pain relief itself 
[3]. Wilson et al., in their randomized trial, reported a 19% conversion rate from RPCA to 
epidural analgesia [11]. This difference in incidence may be attributable to the free choice of 
remifentanil in our study [16]. Our findings are in agreement with those who considered 
RPCA an attractive option for analgesia with acceptable satisfaction scores, particularly for 
multiparas, who usually took the advantage of fast delivery combined with rapid availability 
and short use of pain relief [3].  
Our results confirm the well-known risk of respiratory complications associated with RPCA 
[8]. While the rates of adverse effects appear high, these rates are similar to those reported in 
earlier studies [4, 14, 16, 17]. Nevertheless, no clinically important hypoventilation or other 
severe complications were encountered in any of these cases. That could be attributed to 
obligatory use of supplemental oxygen in all our parturients. Previous studies have 
demonstrated maternal desaturation in 40–70% of women using RPCA, with supplemental 
 
 
oxygen reducing the overall number but not the severity of episodes [14, 18]. Somewhat 
encouragingly, poorer Apgar scores or lower neonatal pH have not been found to correlate 
with episodes of maternal desaturation [18, 19]. Moreover, all women with RPCA in our unit 
are monitored with constant presence of a midwife which enables a prompt response to 
clinically significant hypoventilation. This, however, may not be universally feasible due to 
increasing midwifery vacancies and a rise in the proportion of units in our country which 
report insufficient findings to meet even the current demands on service [20].  
As with previous reports, no adverse neonatal outcomes were observed with CSEA or RPCA 
in our study [2–4,7, 8, 15, 17, 21].   Neither was there any difference observed in the first and 
second stage labour duration. That could be attributed to a higher cumulative dose of oxytocin 
used in the CSEA group [22]. A retrospective analysis comparing RPCA and epidural 
analgesia with respect to labour outcomes found a shorter active labour and a higher rate of 
spontaneous delivery in the RPCA group [23]. The reason, according to experimental studies, 
is that epidural analgesia blocks a spinal reflex release of oxytocin and subsequently 
prostaglandin F, which results in prolonged labour. Furthermore, lumbar spinal blockade by 
transection of the vagal or pelvic nerves suppress cervical ripening and uterine contractions 
and delays birth [24, 25]. 
Our study has limitations. First, due to its observational nature it could not exclude potential 
biases and confounders. For instance, pain scores, satisfaction and side effects were recorded 
by a non-blinded observer, which may favour bias. Second, the satisfaction with labour 
experience, including the pain-relief satisfaction during labour, depends heavily on the 
progress of labour and maternal as well as neonatal outcomes. Therefore, we compared 
progress of labour, need for labour augmentation and perinatal outcomes in the two study 
groups. Since no significant differences were observed, the groups may be considered as 
comparable. Nevertheless, despite the limitations of the study’s design, giving women a 
choice in selecting their mode of labour analgesia may have significantly contributed to their 








Under condition of our study, CSEA provided superior analgesia and a higher satisfaction rate 
compared to RPCA in multiparous women. Nevertheless, RPCA appeared to provide a 
satisfactory experience, suggesting it could be used when neuraxial analgesia is not quickly 
available, if contraindicated or not preferred by women or obstetricians. In this case, 
monitoring with a constant presence of a competent midwife is mandatory for timely 
management of clinically significant hypoventilation.  
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Table 1. Patient characteristics and obstetric outcomes 
 CSEA 
n = 81 
RPCA 
n = 80 
p-value 
ASA physical status (2/3) 76/5 74/6 0.766 
Maternal age [y] 33 ± 5 32 ± 5 0.760 
Weight [kg] 81± 13 84 ± 14 0.147 
BMI [kg m-2] 29.1 ± 4.7 29.8 ± 5.4 0.519 
Gestational age [weeks] 39 ± 1 39 ± 2 0.364 
Parity 2 [2–2] 2 [2–2] 0.913 
Cervix dilatation at initiation of analgesia [cm] 4.0 ± 0.8 4.4 ± 0.6 0.004 
Duration of 1st stage of labour [min] 90 ± 59 78 ± 47 0.156 
Duration of 2nd stage of labour [min] 22 ± 16 19 ± 15 0.222 
Speed of cervical dilation > 1.5 cm h-1 63 (78%) 69 (86%) 0.218 
Labour induction  34 (42%) 28 (35%) 0.419 
Augmentation with oxytocin 74 (91%) 71 (89%) 0.609 
         Cumulative oxytocin dose (IU) 14 ± 8 11 ± 6 0.017 
Instrumental delivery 0 (0%) 0 (0%) 0.999 
Episiotomy 74 (91%) 71 (89%) 0.713 
Postpartum haemorrhage ≥ 500 mL 4 (5%) 3 (4%) 0.999 
Perineal tear ≥ 3rd degree 1 (1%) 0 (0%) 0.999 
Vertex OA position 77 (94%) 75 (94%) 0.720 
Vertex OP position 3 (4%) 5 (6%) 0.720 
Birth weight [g] 3509 ± 471 3469 ± 430 0.581 
Head circumference[cm] 35.2 ± 1.3 34.9 ± 1.2 0.130 
Apgar 1 min 9 [9–9] 9 [9–9] 0.999 
Apgar 5 min 9 [9–9] 9 [9–9] 0.999 
Umbilical artery pH 7.25 ± 0.09 7.28 ± 0.08 0.058 
Umbilical vein pH 7.32 ± 0.07 7.34 ± 0.07 0.233 
Foetal bradycardia 2 (2%) 4 (5%) 0.277 
Values are number (proportion %), mean ± SD or median [IQR];  ASA — American Society 
of Anaesthesiologist’s physical status; CSEA — combined spinal and epidural analgesia; 
RPCA — remifentanil patient-controlled analgesia 
 
 
Table 2. Numerical rate scale (NRS) scores in multiparous women 




NRS at inclusion 8.0 ± 1.7, n = 81   7.9 ± 1.4, n = 80 0.1 0.999 
NRS at 15 min 1.7 ± 2.5, n = 80** 6.1 ± 1.7, n = 78** 4.4 < 0.0001 
NRS at 30 min 1.3 ± 2.2, n = 77** 6.3 ± 1.9, n = 71** 5.0 < 0.0001 
NRS at 45 min 1.8 ± 2.3, n = 70** 6.4 ± 2.0, n = 65** 4.6 < 0.0001 
NRS at 60 min 2.0 ± 2.1, n = 58** 7.0 (1.9), n = 57* 5.0 < 0.0001 
NRS at 90 min 3.2 ± 2.4, n = 47** 7.6 ± 1.9, n = 40 4.4 < 0.0001 
NRS at 120 min 5.0 ± 2.2, n = 32** 8.0 ± 1.9, n = 22 3.0 < 0.0001 
NRS at 150 min 5.8 ± 2.7, n = 19* 8.7 ± 1.3, n = 9 2.9 0.008 
NRS at 180 min 5.4 ± 2.5, n = 10* 7.5 ± 1.0, n = 4 2.1 0.370 
Values are expressed as means ± SD. RPCA — remifentanil patient-controlled analgesia; 
CSEA — combined spinal-epidural analgesia. Effect size, absolute difference between means. 
#p values for RPCA vs CSEA at the same time point; *p = 0.01–0.05, **p < 0.0001vs NRS 


























Number of boluses needed 2 [1–3] 22 [14–34] NA 
Pruritus  
18 (22%) 1 (1%) 
< 
0.0001 
Nausea or vomiting 4 (5%) 4 (5%) 0.999 
Temperature at initiating analgesia [°C] 36.7 ± 0.3 36.6 ± 0.3 0.292 
Temperature within 1 hour after delivery [°C] 37.0 ± 0.4 36.9 ± 0.5 0.297 
Systolic blood pressure drop > 20 mmHg 6 (8%) 4 (5%) 0.746 
Heart rate drop below 60 min-1 1 (1%) 0 (0%) 0.999 
Desaturation (SpO2 < 94%) NA 27 (34%)  
Bradypnea (respiratory rate < 8 min-1) NA 17 (21%)  
Apnoea (respiratory pause > 20 s) NA 20 (25%)  
The highest sedation score during labour:    
          1 (alert) 80 (99%) 66 (82%) 0.0003 
          2 (slightly drowsy) 1 (1%) 12 (15%) 0.0012 
          3 (drowsy) 0 (0%) 2 (3%) 0.245 
          ≥ 4 (very drowsy, unarousable) 0 (0%) 0 (0%) 0.999 
Values are expressed as an absolute number (proportion %), mean ± SD or median [IQR]; 
RPCA — remifentanil patient-controlled analgesia; CSEA — combined spinal-epidural 




















Figure 2. Relative numerical rating scale (NRS) score changes from the baseline value in 
multiparous women. Remifentanil patient-controlled analgesia (RPCA) (■) or combined 
spinal-epidural analgesia (CSEA) (●) during labour. Data are medians and inter-quartile 
ranges. *p < 0.01, **p < 0.0001 vs baseline NRS score of the same study group; #p < 0.0001 
relative NRS score changes of the RPCA vs CSEA study group at the same time point 
(Friedman test)  
 
 
 
  
 
 
 
